.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing tardive dyskinesia (TD) requires a precise pharmacological approach to balance psychiatric stability and motor control. Recent research highlights that using VMAT2 inhibitors for TD offers significant advantages over traditional anticholinergic medications. Traditionally, clinicians used anticholinergics for drug-induced movement disorders. However, evidence now shows these drugs may worsen TD symptoms rather than provide relief. Consequently, the medical community is shifting toward more selective treatments like valbenazine and deutetrabenazine.
A study by Hsu TW et al. recently addressed the safety profiles of different TD treatments through target trial emulation. This advanced research method mimics a randomized controlled trial using real-world data. Specifically, the authors emphasized the importance of "time zero alignment." By ensuring that follow-up starts exactly when treatment begins, researchers can avoid immortal time bias. The findings demonstrate that VMAT2 inhibitors lead to fewer adverse outcomes than anticholinergics. Moreover, these selective agents provide more consistent control of involuntary movements. Therefore, VMAT2 inhibitors represent a safer and more reliable therapeutic choice for modern practice.
Current clinical guidelines now identify VMAT2 inhibitors as the first-line treatment for moderate to severe TD. Unlike anticholinergics, which target acetylcholine receptors, VMAT2 inhibitors deplete presynaptic dopamine. This mechanism directly addresses the pathophysiology of dopamine supersensitivity. Furthermore, VMAT2 inhibitors avoid the cognitive decline and dry mouth common with anticholinergic use. In contrast, anticholinergics are only recommended for acute extrapyramidal side effects, not for TD. Consequently, practitioners must differentiate between these movement disorders to ensure patients receive the correct intervention.
Target trial emulation allows researchers to structure observational studies like clinical trials. By using techniques like time zero alignment, it removes common biases that occur when comparing drugs with different initiation times. This provides more accurate safety and efficacy data for clinicians.
Generally, medical experts discourage using anticholinergics for TD. While they help with acute parkinsonism, they can mask TD symptoms or even exacerbate the underlying involuntary movements. Transitioning to VMAT2 inhibitors is the current standard of care.
Disclaimer: This content is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.
References
Hsu TW et al. Response to [Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia]. Psychiatry Clin Neurosci. 2026 Jun 17. doi: 10.1111/pcn.70095. PMID: 42308002.
Keepers GA et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020;177(9):868-872.
Tarsy D. Treatment of tardive dyskinesia. UpToDate. Accessed June 2026.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This article discusses the superiority of VMAT2 inhibitors over anticholinergics for tardive dyskinesia management, highlighting the role of target trial emulation and time zero alignment in establishing clinical safety.
4 months ago
Depemokimab offers twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, significantly cutting exacerbations and hospital admissions.
2 days back
A novel copper metal-organic framework hydrogel remodels the uterine microenvironment to stimulate robust endometrial regeneration, reduce intrauterine fibrosis, and restore reproductive fertility, offering a groundbreaking strategy for managing refractory endometrial damage and Asherman syndrome.
3 days back
New research reveals that non-ablative radiotherapy suppresses ventricular tachycardia by increasing conduction velocity via NaV1.5 upregulation and action potential prolongation. However, sustained sodium current elevation and depressed calcium handling highlight the need for careful clinical translation.
5 days back
A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 days back
A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
3 days back
